Abstract:BACKGROUND & AIMS: Chromoendoscopy with iodine staining is used to identify esophageal squamous dysplasia and esophageal squamous cell carcinomas (ESCCs)-absence of staining indicates suspicious regions of dysplasia. However, screening detects precancerous lesions (mild and moderate dysplasia) that do not require immediate treatment; it is a challenge to which lesions are at risk for progression. We investigated the association between absence of iodine staining at chromoendoscopy screening and lesion progression using 6 years of follow-up data from a population-based randomized controlled trial in China. We then constructed and validated a model to calculate risk of progression to severe dysplasia, carcinoma in situ, or ESCC. METHODS: We collected data from 1468 participants (45-69 years old) who were either negative for iodine staining at a baseline chromoendoscopy or found to have mild or moderate dysplasia in histologic analysis of biopsies in the Endoscopic Screening for Esophageal Cancer study in China, from January 2012 through September 2016; 788 of these participants were re-examined by endoscopy after a median interval of 4.2 years (development cohort). We investigated the association between absence of iodine staining and progression of esophageal lesions using Cox prediction models, considering corresponding baseline pathology findings and patient answers to a comprehensive questionnaire. Patients who did not receive a follow-up examination (n = 680) was used as the validation cohort; outcome events in these patients were identified by annual door to door active interviews or linkage with local electronic registry data. The primary outcome was incident esophageal severe dysplasia, carcinoma in situ, or ESCC. RESULTS: In the development cohort, 11 lesions that did not stain with iodine but were classified as not dysplastic in the histology analysis were found to be severe dysplasia, carcinoma in situ, or ESCC at the follow-up evaluation. These lesions accounted for 39.3% of all progressed lesions (n = 28). In the validation cohort, 6 patients with lesions did not stain with iodine but were classified as not dysplastic by histology had a later diagnosis of ESCC, determined from medical records; these patients accounted for 50.0% of all patients with lesion progression (n = 12) until the closing date of this study. We developed a model based on patient age, body mass index, pathology findings, and baseline iodine staining to calculate risk for severe dysplasia, carcinoma in situ, or ESCC. It identified patients for severe dysplasia, carcinoma in situ, or ESCC in the development set with an area under the curve of 0.868 (95% CI, 0.817-0.920) and in the validation set with an area under the curve of 0.850 (95% CI, 0.748-0.952). Almost no cases would be missed if subjects determined to be high or intermediate-high risk subjects by the model were included in surveillance. CONCLUSIONS: Absence of iodine staining at baseline chromoendoscopy identifies esophageal lesions at risk of progression with a high level of sensitivity. A model that combines results of iodine chromoendoscopy with other patient features identifies patients at risk of lesion progression with greater accuracy than histologic analysis of baseline biopsies.

Persistence of Lugol-unstaining is associated with an increased risk of progression to malignancy in the esophagus

Multiple Lugol‐unstained lesions predict higher cumulative risk of malignance in the esophagus

Size of Lugol-unstained lesions as a predictor for risk of progression in premalignant lesions of the esophagus

Lugol-unstained Lesions Location in the Esophagus Affects the Detection Rate of Malignancy: a Population-Based Study.

Absence of Lugol Staining Indicates Initiation of Esophageal Squamous Cell Carcinoma: A Combined Genomic and Epidemiologic Study.

How Should Extra‐large Lugol‐unstained Lesions of the Esophagus Be Treated? Results from a Population‐based Cohort Study

Absence of Iodine Staining Associates with Progression of Esophageal Lesions in a Prospective Endoscopic Surveillance Study in China.

Clinical characteristic of esophageal cancer without lugol‐voiding lesions in the background esophagus

Lugol Chromoendoscopic Screening for Esophageal Dysplasia/early Squamous Cell Carcinoma in Patients with Esophageal Symptoms in Low-Risk Region in China.

Absence of NOTCH1 Mutation and Presence of CDKN2A Deletion Predict Progression of Esophageal Lesions.

Lugol Chromoendoscopy Detects Esophageal Dysplasia With Low Levels Of Sensitivity In A High-Risk Region Of China.

Determining an Evidence-Based Surveillance Target and Respective Intervals for Esophageal Squamous Cell Carcinoma Following Screening: A Population-Based Cohort Study in China

Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region

Analysis of White-Light Imaging-Based Features Predictive for Determination of Lesion Depths of Superficial Flat Esophageal Squamous Cell Carcinoma: a Retrospective Multicenter Study from China

Endoscopic surveillance for premalignant esophageal lesions: A community-based multicenter, prospective cohort study

Value of endoscopic Lugol's chromoendoscopy in diagnosis of esophageal lesions

Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma in Taiwan

Demarcation of early esophageal squamous cell carcinoma during endoscopic submucosal dissection: A comparison study between Lugol's iodine staining and narrow-band imaging

High incidence of lung cancer death after curative endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma

Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial

Early esophageal cancer or precancerous lesions treated by endoscopic resection: a single-center retrospective study of 368 cases